Detail akcie Kezar Life Rg online

Business Summary: Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The Company is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Kezar Life Sciences Inc revenues was not reported. Net loss decreased 35% to $41.5M. Lower net loss reflects Clinical stage biotechnology segment loss decrease of 29% to $32.2M. Basic Earnings per Share excluding Extraordinary Items increased from -$8.72 to -$5.67.